We Power Antibody Discovery
US FDA Approves Adagene IO Agonist IND for Solid Tumor and Non-Hodgkin Lymphoma Ph1 Trial
Adagene Raises $50 Million in Series C Funding
Adagene (Suzhou China) is an innovative antibody engineering and discovery company for global unmet medical needs. Utilizing its proprietary Dynamic Precision Library Platform (DPL), Adagene is developing immuno-oncology antibodies against novel epitopes that give unique product profiles that have potential to succeed where other groups have failed. Adagene is showcasing its exceptional antibody engineering capabilities by building franchises of products with multi-specific antibodies that are cross-species reactive to accurately find the correct structural relationship and drug combinations to find the ideal therapeutic. Also, Adagene is developing a third-generation technology to enhance the therapeutic window for antibodies. Adagene has received notification from the FDA to proceed on its IND application to study its lead product in patients with advanced solid tumors and non-Hodgkin lymphoma which exhibits robust single agent and combination activity in multiple pre-clinical models. Also Adagene plans to file INDs in the Australia and China in mid-2018. Adagene’s second and third products are currently anticipated filing global INDs in 2019 and 2020. The company’s management team is composed of industry veterans with proven track record in therapeutic antibody R&D. Adagene is backed by top notch global venture funds such as F-Prime Capital Partners, Eight Roads Ventures, 6 Dimensions Capital, GP Healthcare Capital, New World TMT Ltd and Sequoia China. The company has raised over $85 million through its series A to C financing.
SUZHOU, China, July 9, 2018 /PRNewswire/ -- Adagene, Inc., an innovative antibody engineering and discovery company, has received notification from the FDA to proceed on its Investigational New Drug (IND) application to study its lead product (ADG-106) in patients with advanced solid tumors and non-Hodgkin lymphoma.2018.07.09